BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:01 AM
 | 
May 03, 2018
 |  BC Extra  |  Company News

Ferring gains option for bladder cancer gene therapy

FKD Therapies Oy (Kuopio, Finland) granted Ferring Pharmaceuticals A/S (Saint-Prex, Switzerland) an option to license exclusive, worldwide commercial rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3; formerly instiladrin). The adenovirus serotype 5 (Ad5) vector containing interferon...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >